(917) 310-3371
Brixadi
Extended-release buprenorphine with weekly and monthly formulations, administered subcutaneously through a restricted REMS pathway.
Brixadi injections in NYC and Long Island
Weekly or monthly extended-release buprenorphine evaluation, insurance coordination, certified-pharmacy delivery, and in-clinic treatment planning.
Brixadi is an FDA-approved treatment for moderate to severe opioid use disorder. The first appointment is an evaluation, not an automatic injection. A clinician reviews current opioid and buprenorphine use, confirms tolerability, and coordinates the medication before an administration visit is scheduled.
The first booking is an evaluation
Coverage, pharmacy delivery, and the administration appointment are coordinated after the clinician confirms that Brixadi is an appropriate option.
What Brixadi is and who it may help
Brixadi contains buprenorphine, a partial opioid agonist used to reduce withdrawal symptoms and cravings as part of treatment for opioid use disorder.
Moderate to severe opioid use disorder
The FDA-approved indication is for patients with moderate to severe opioid use disorder, not for occasional opioid use or pain treatment alone.
Buprenorphine tolerability
A patient may already be receiving buprenorphine or may initiate with a supervised transmucosal dose before injection, as directed by the prescriber.
Weekly and monthly formulations
The two formulations have different strengths, dosing schedules, and injection-site instructions. They are prescribed, not chosen as interchangeable consumer products.
How the Brixadi care path works
1. Clinical evaluation
Review opioid use, withdrawal and cravings, prior treatment, medicines and substances, health history, overdose risk, and treatment goals.
2. Tolerability and dose plan
Confirm current buprenorphine treatment or use a supervised transmucosal dose when the prescriber determines that step is appropriate.
3. Coverage and delivery
Coordinate insurance, prior authorization when required, and patient-specific delivery from a REMS-certified pharmacy to the healthcare setting.
4. Administration and follow-up
Schedule the injection after the medication arrives, then monitor response, side effects, cravings, substance use, and the timing of the next dose.
Brixadi, Sublocade, Suboxone, and Vivitrol
These treatments answer different clinical and practical questions. A medication is selected after assessment, not from a marketing comparison alone.
Sublocade
Once-monthly extended-release buprenorphine administered subcutaneously through its own restricted REMS pathway.
Suboxone and other transmucosal buprenorphine
Medication taken under the tongue or inside the cheek, with flexible dose adjustment and regular prescribing follow-up.
Vivitrol
Monthly extended-release naltrexone, an opioid antagonist that requires an opioid-free period before treatment for opioid use disorder.
Important safety and access facts
- Brixadi must be administered subcutaneously by a healthcare provider. Intravenous administration can cause serious harm or death.
- The medication is not dispensed to patients through a retail pharmacy. Certified settings and pharmacies must follow the Brixadi REMS requirements.
- Alcohol, benzodiazepines, sedatives, and other central nervous system depressants can increase the risk of respiratory depression and overdose.
- Tell clinicians about liver disease, pregnancy or breastfeeding, planned surgery, acute pain treatment, and every medicine or substance you use.
- Discuss access to naloxone or another opioid overdose reversal agent, and call 911 for a suspected overdose.
Choose a clinic for your Brixadi evaluation
Medication is not held for walk-in administration. Approval, certified-pharmacy delivery, and the injection appointment are coordinated after clinical review.
Bronx
174th Street
932 E 174th St, Bronx, NY 10460
Choose this clinic for the initial addiction medicine evaluation. Medication approval, certified-pharmacy delivery, and injection timing are coordinated after clinical review.
Queens
Astoria
37-15 23rd Ave, Astoria, NY 11105
Choose this clinic for the initial addiction medicine evaluation. Medication approval, certified-pharmacy delivery, and injection timing are coordinated after clinical review.
Bronx
Bartow Mall
2063A Bartow Ave, Bronx, NY 10475
Choose this clinic for the initial addiction medicine evaluation. Medication approval, certified-pharmacy delivery, and injection timing are coordinated after clinical review.
Brooklyn
Crown Heights
341 Eastern Pkwy, Brooklyn, NY 11216
Choose this clinic for the initial addiction medicine evaluation. Medication approval, certified-pharmacy delivery, and injection timing are coordinated after clinical review.
Long Island
Hicksville
232 W Old Country Rd, Hicksville, NY 11801
Choose this clinic for the initial addiction medicine evaluation. Medication approval, certified-pharmacy delivery, and injection timing are coordinated after clinical review.
Queens
Jackson Heights
80-10 Northern Blvd, Jackson Heights, NY 11372
Choose this clinic for the initial addiction medicine evaluation. Medication approval, certified-pharmacy delivery, and injection timing are coordinated after clinical review.
Queens
Jamaica
90-18 Sutphin Blvd, Jamaica, NY 11435
Choose this clinic for the initial addiction medicine evaluation. Medication approval, certified-pharmacy delivery, and injection timing are coordinated after clinical review.
Queens
Long Island City
30-07 36th Ave, Astoria, NY 11106
Choose this clinic for the initial addiction medicine evaluation. Medication approval, certified-pharmacy delivery, and injection timing are coordinated after clinical review.
Long Island
Mineola
135 Mineola Blvd, Mineola, NY 11501
Choose this clinic for the initial addiction medicine evaluation. Medication approval, certified-pharmacy delivery, and injection timing are coordinated after clinical review.
Manhattan
StuyTown
259 1st Ave, New York, NY 10003
Choose this clinic for the initial addiction medicine evaluation. Medication approval, certified-pharmacy delivery, and injection timing are coordinated after clinical review.
Brooklyn
Williamsburg
308 Graham Ave, Brooklyn, NY 11211
Choose this clinic for the initial addiction medicine evaluation. Medication approval, certified-pharmacy delivery, and injection timing are coordinated after clinical review.
Related opioid-use-disorder care
Buprenorphine treatment
Evaluation of oral and long-acting buprenorphine options for opioid use disorder.
Suboxone treatment
Buprenorphine-naloxone evaluation, medication planning, and ongoing follow-up.
Sublocade injections
Monthly extended-release buprenorphine evaluation, access coordination, and in-clinic administration planning.
Vivitrol treatment
Extended-release naltrexone evaluation for opioid or alcohol use disorder when clinically appropriate.
Same-day Suboxone evaluation
Fast assessment without promising that medication can or should start before timing and safety are reviewed.
Kratom dependence treatment
Assessment of withdrawal, product type, 7-OH exposure, opioid overlap, and appropriate next steps.
Clinical sources
These public clinical and regulatory sources were checked on August 1, 2026. They support the general information and do not replace an individual medical evaluation.
FDA prescribing information
The current FDA-approved indication, dosing, boxed warning, REMS, and safety information.
DailyMed drug label
The current label and patient medication guide in an accessible web format.
New York OASAS XR-buprenorphine guidance
New York guidance on prescribing, certified pharmacy delivery, storage, administration, and coverage.
Brixadi questions
Brixadi is an extended-release buprenorphine injection approved for moderate to severe opioid use disorder. It is available in weekly and monthly formulations and is administered subcutaneously by a healthcare provider.
Both schedules exist. The prescriber selects the formulation and dose after reviewing current buprenorphine treatment, clinical response, treatment goals, and the FDA-approved dosing guidance.
Brixadi may be used for a patient already receiving buprenorphine or after the patient has initiated treatment with a single dose of a transmucosal buprenorphine product. The clinician confirms tolerability and clinical stability before injection.
Both are extended-release buprenorphine injections for opioid use disorder. Brixadi has weekly and monthly formulations, while Sublocade is monthly. Dose conversion, injection sites, label instructions, and access workflows differ, so the products are not interchangeable without prescriber review.
No. Brixadi is available only through its restricted REMS distribution program. A certified pharmacy sends it to a certified healthcare setting, where a healthcare provider administers it.
The first visit reviews opioid use history, current or prior buprenorphine treatment, withdrawal and cravings, other medicines and substances, and overdose risk. It also covers health questions, insurance, and the treatment schedule.
The care team can review benefits and coordinate the prescription, prior authorization, certified pharmacy delivery, and administration appointment. Coverage and out-of-pocket cost depend on the health plan and pharmacy benefit.
The FDA label lists injection-site pain, headache, constipation, nausea, injection-site redness or itching, insomnia, and urinary tract infection among commonly reported adverse reactions. The prescriber reviews serious risks, interactions, and when urgent care is needed.
Tell every treating clinician that you receive extended-release buprenorphine. Acute pain and anesthesia may require a coordinated plan and close monitoring. Do not try to change or remove the medication yourself.
The FDA label advises clinicians to discuss access to an opioid overdose reversal agent such as naloxone when starting or renewing treatment. Naloxone does not replace emergency care; call 911 for a suspected overdose.
Contact the prescribing team promptly. Do not double a dose or substitute another buprenorphine product without instructions. The clinician will review timing, symptoms, and the appropriate next step.
Focused care or a more supported outpatient program
Nao Medical operates a New York State OASAS-certified outpatient addiction treatment program. The first visit can focus on the immediate clinical question and medication planning when relevant, or the care plan can include counseling, recovery support, and closer follow-up when that is wanted or clinically recommended.
Focused clinical visits
Patients can request a private evaluation centered on the immediate concern, prescribing or injection planning when applicable, monitoring, and practical next steps. Medication is never automatic; eligibility and safety still require clinician review.
Counseling is available
Patients who want more support can add counseling, relapse-prevention work, care coordination, and recovery follow-up through the outpatient addiction program.
Confidential intake first
After scheduling, complete the confidential addiction intake form when it is sent. It helps the team review current substance use, prior treatment, medications, insurance, and the safest visit type.
Nao Medical accepts Medicaid and many major insurance plans, including Medicare, Healthfirst, MetroPlus, Fidelis, UnitedHealthcare and UnitedHealthcare Community Plan, EmblemHealth, Aetna, Cigna, and Blue Cross Blue Shield. Coverage varies by visit, medication, pharmacy benefit, testing, counseling, and prior authorization. Review addiction-treatment insurance support.
Brixadi has weekly and monthly injection schedules
Brixadi is extended-release buprenorphine for moderate to severe opioid use disorder. The prescriber selects a weekly or monthly formulation and dose after reviewing current treatment, tolerability, symptoms, goals, and the FDA-approved dosing instructions.
Weekly Brixadi
A weekly schedule can support dose finding or a shorter interval when the clinical plan calls for it.
Monthly Brixadi
A monthly schedule may reduce day-to-day medication handling after the clinician confirms the appropriate formulation and dose.
Evaluation before injection
The medication must be ordered and delivered through the required pathway. A booking is an evaluation, not confirmation that an injection is in stock or will be given that day.
Health information notice
General information only. The information here is not medical advice and does not replace diagnosis, treatment, or guidance from a licensed clinician.
Content was updated August 2, 2026 from the cited sources and Nao Medical's current service information. Medical guidance, prescribing information, medication availability, and insurance rules can change. A licensed clinician must confirm current information and determine each patient's eligibility, testing, treatment, administration setting, and follow-up. Call 911 for a medical emergency. Contact Nao Medical with a question or correction.